Metabolically Healthy, but Obese Individuals and Associations with Echocardiographic Parameters and Inflammatory Biomarkers: Results from the CARLA Study.
cardiac remodeling
inflammatory biomarkers
obesity phenotypes
visceral adipose tissue
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
05
2020
accepted:
02
07
2020
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
22
8
2020
Statut:
epublish
Résumé
The research on heterogeneity among obese individuals has identified the metabolically healthy, but obese (MHO) phenotype as a distinct group that does not experience the typical cardiovascular-related diseases (CVD). It is unclear if this group differs with regard to preconditions for CVDs. Our aim was to assess differences in echocardiographic parameters and inflammatory biomarkers between MHO and metabolically healthy, normal weight individuals (MHNW). The analyses used data from 1412 elderly participants from a German population-based cohort study (CARLA), which collected detailed information on demographic, biochemical, and echocardiographic variables. Participants were subdivided into four groups (MHNW, MHO, MUNW (metabolically unhealthy, normal weight) and MUO (metabolically unhealthy, obese)) based on BMI≥30 kg/m The MHO individuals were on average 64.2±8.4 years old, with a higher proportion of women (71.6%), low percentage of smokers, larger waist circumference (109.3±10.5 cm vs 89.1±10.8 cm, p<0.0001) and higher odds ratios for hsCRP, IL-6 and sTNF-RI compared to MHNW individuals. Linear regression models revealed greater left atrial (LA) diameter (2.73 (95% CI: 1.35-4.11) mm), LA volume (7.86 (95% CI: 2.88-12.83) mL), and left ventricular mass index (LVMI) (11.82 (95% CI: 4.43-19.22) g/m The MHO phenotype is associated with echocardiographic markers of cardiac remodeling (LA diameter, volume and LVMI) and higher odds ratios for inflammatory biomarkers.
Identifiants
pubmed: 32821138
doi: 10.2147/DMSO.S263727
pii: 263727
pmc: PMC7419616
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2653-2665Informations de copyright
© 2020 Efremov et al.
Déclaration de conflit d'intérêts
The Authors declare no conflicts of interest in this work.
Références
Hypertension. 2010 Jul;56(1):91-8
pubmed: 20458004
Metabolism. 2019 Apr;93:18-24
pubmed: 30639450
Mediators Inflamm. 2012;2012:456456
pubmed: 23091306
J Am Coll Cardiol. 2014 Mar 25;63(11):1071-8
pubmed: 24345592
Circ Heart Fail. 2015 Sep;8(5):897-904
pubmed: 26175540
Circulation. 2007 Sep 11;116(11):1234-41
pubmed: 17709633
Horm Metab Res. 2013 Dec;45(13):1009-19
pubmed: 24277504
Diabetes Care. 2013 Aug;36(8):2388-94
pubmed: 23491523
BMC Cardiovasc Disord. 2005 Nov 11;5:33
pubmed: 16283930
Clin Nutr. 2019 Apr;38(2):820-828
pubmed: 29525513
J Clin Endocrinol Metab. 2019 Mar 1;104(3):738-752
pubmed: 30339231
PLoS One. 2017 Dec 28;12(12):e0190528
pubmed: 29284058
Int J Obes (Lond). 2006 Oct;30(10):1529-34
pubmed: 16552406
J Intern Med. 2018 Nov;284(5):450-463
pubmed: 30144199
BMC Public Health. 2014 Jan 08;14:14
pubmed: 24400816
Circulation. 1995 Aug 15;92(4):805-10
pubmed: 7641360
Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G518-25
pubmed: 17023554
Obes Res. 2005 Jun;13(6):1116-22
pubmed: 15976155
Exp Clin Endocrinol Diabetes. 2014 Feb;122(2):87-91
pubmed: 24554508
Eur J Endocrinol. 2015 Nov;173(5):703-8
pubmed: 26286585
J Clin Densitom. 2017 Apr - Jun;20(2):256-264
pubmed: 28238606
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Clin Invest. 2006 Nov;116(11):3015-25
pubmed: 17053832
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
Diabetes Metab. 2004 Dec;30(6):569-72
pubmed: 15671927
Med Sci Sports Exerc. 2012 Jan;44(1):84-8
pubmed: 21659902
Int J Obes (Lond). 2018 Mar;42(3):302-309
pubmed: 29064474
Eur J Epidemiol. 2009;24(3):123-42
pubmed: 19199053
J Hypertens. 2011 Sep;29(9):1765-72
pubmed: 21826021
Int J Obes (Lond). 2011 Jul;35(7):971-81
pubmed: 20975726
J Hum Hypertens. 2013 Jan;27(1):13-7
pubmed: 22237633
Cytokine Growth Factor Rev. 1996 Oct;7(3):231-40
pubmed: 8971478
Circulation. 1998 Apr 14;97(14):1382-91
pubmed: 9577950
Diabetes Res Clin Pract. 2005 Jul;69(1):29-35
pubmed: 15955385
Int J Obes (Lond). 2016 Jan;40(1):153-61
pubmed: 26271188
Obes Res Clin Pract. 2019 Nov - Dec;13(6):548-554
pubmed: 31711772
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Trends Immunol. 2010 Jun;31(6):228-35
pubmed: 20434953
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
J Lipid Res. 2011 Mar;52(3):480-8
pubmed: 21148461
Prev Med. 2017 Jan;94:7-11
pubmed: 27840116
J Am Soc Echocardiogr. 2004 Oct;17(10):1086-119
pubmed: 15452478
Metabolism. 2016 Jan;65(1):73-80
pubmed: 26683798
J Biol Chem. 2005 Sep 30;280(39):33588-98
pubmed: 16079133
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Curr Opin Lipidol. 2010 Feb;21(1):38-43
pubmed: 19915462
J Am Coll Cardiol. 2018 May 1;71(17):1857-1865
pubmed: 29699611
Metabolism. 2001 Dec;50(12):1499-504
pubmed: 11735101
Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1189-H1201
pubmed: 27591224
Cardiovasc Diabetol. 2009 Nov 12;8:58
pubmed: 19909503